Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 9561013, 4 pages
https://doi.org/10.1155/2017/9561013
Case Report

Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review

1Division of Internal Medicine of the Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
2Division of Hematology Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
3Hematology Section, Medical Service, Veterans Affairs Medical Center, Washington, DC, USA
4Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
5Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Washington, DC, USA

Correspondence should be addressed to Geraldine P. Schechter; vog.av@rethcehcS.enidlareG

Received 16 June 2017; Accepted 17 August 2017; Published 24 September 2017

Academic Editor: Ramon Tiu

Copyright © 2017 Hind Rafei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Clinical Practice Points. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.